AHA GUIDELINES Bundle (free trial)

Dyslipidemia 2026

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1543908

Contents of this Issue

Navigation

Page 38 of 105

39 4.2.3.5. Polygenic Risk Scores 4.2.3.6. Selective Imaging of Subclinical Atherosclerosis (Men ≥40 or Women ≥45 Years) COR LOE Recommendations 1 B-R 1. In adults at intermediate risk and select adults at borderline risk with no prior ASCVD, if the decision regarding LLT remains uncertain, a CAC score should be used for further risk stratification and to guide the decision to withhold, postpone, or initiate therapy. 2a B-NR 2. In adults at intermediate risk or select adults at borderline risk who undergo CAC testing, if the CAC score is 0 Agatston units (AU), and there is preference to avoid LLT and focus on lifestyle management, and no higher risk conditions (FH or severe hypercholesterolemia >190 mg/dL, diabetes and age >40 years, current cigarette smoking, strong family history of premature ASCVD) are present, it is reasonable to defer therapy and reassess with repeat CAC testing in 3 to 7 years to personalize management. 1 B-NR 3. In adults at intermediate risk and select adults at borderline risk, if the CAC score is >0 AU, it is recommended to initiate LLT, particularly if the CAC score is ≥100 AU or ≥75th standardized percentile to reduce ASCVD risk. 2a B-NR 4. In adults at intermediate or high risk with no prior ASCVD, if there is uncertainty about the intensity of LLT, a CAC score can be useful to refine treatment goals and decide whether to intensify LLT. 1 B-NR 5. In adults with no prior ASCVD, if incidental CAC is identified on noncardiac computed tomography (CT) scans (eg, by visual estimation or a validated artificial-intelligence based algorithm), the presence of coronary atherosclerosis should be considered during decision-making about initiation or intensification of LLT to reduce ASCVD risk. 2b B-NR 6. In adults with no prior ASCVD who are likely to have a high burden of noncalcified plaque (eg, inflammatory disorders, persons living with HIV, and diabetes), selective use of coronary CT angiography (CCTA) may be useful to inform risk assessment and guide decisions regarding treatment intensity of LLT.

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Dyslipidemia 2026